Screener
Vir Biotechnology, Inc. VIR Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Vir Biotechnology, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
FAQ
- What is Vir Biotechnology, Inc.'s debt-to-equity?
- Vir Biotechnology, Inc. (VIR) reported debt-to-equity of 0.1× in Q2 2026.
- How has Vir Biotechnology, Inc.'s debt-to-equity changed year-over-year?
- Vir Biotechnology, Inc.'s debt-to-equity decreased by 12.0% year-over-year, from 0.1× to 0.1×.
- What is the long-term trend for Vir Biotechnology, Inc.'s debt-to-equity?
- Over 5 years (2020 to 2025), Vir Biotechnology, Inc.'s debt-to-equity has grown at a 5.2% compound annual growth rate (CAGR), from 0.1× to 0.1×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Vir Biotechnology, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude